References
- Greco FA , HainsworthJD. Tumors of unknown origin. CA Cancer J. Clin.2, 96–115 (1992).
- Stella GM , SenettaR, CassentiAet al. Cancers of unknown primary origin: current perspectives and future therapeutic strategies. J. Transl. Med.10, 12 (2012).
- NCI website, carcinoma of unknown primary . www.cancer.gov/types/unknown-primary/patient/unknown-primary-treatment-pdq.
- Kim KW , KrajewskiKM, JagannathanJPet al. Cancer of unknown primary sites: what radiologists need to know and what oncologists want to know. Am. J. Roentgenol.3, 484–492 (2013).
- NCCN guidelines of occult primary . www.nccn.org/professionals/physician_gls/pdf/occult.pdf.
- Pardoll DM . The blockade of immune checkpoints in cancer immunotherapy. Nat. Rev. Cancer.12, 252–264 (2012).
- Hodi FS , O’DaySJ, McDermottDF, WeberRWet al. Improved survival with ipilimumab in patients with metastatic melanoma. N. Engl. J. Med.363, 711–723 (2010).
- Hamid O , RobertC, DaudAet al. Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. N. Engl. J. Med.369, 134–144 (2013).
- Weber JS , D’AngeloSP, MinorD, HodiFSet al. Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, Phase 3 trial. Lancet Oncol.16, 375–384 (2015).
- Rizvi NA , MazièresJ, PlanchardDet al. Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a Phase 2, single-arm trial. Lancet Oncol.16, 257–265 (2015).
- Borghaei H , Paz-AresL, HornLet al. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. N. Engl. J. Med.17, 1627–39 (2015).
- Garon EB , RizviNA, HuiRet al. Pembrolizumab for the treatment of non-small-cell lung cancer. N. Engl. J. Med.21, 2018–2028 (2015).
- Larkin J , Chiarion-SileniV, GonzalezRet al. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N. Engl. J. Med.1, 23–34 (2015).
- Motzer RJ , EscudierB, McDermottDFet al. Nivolumab versus everolimus in advanced renal-cell carcinoma. N. Engl. J. Med.19, 1803–1813 (2015).
- Hamanishi J , MandaiM, IkedaTet al. Safety and antitumor activity of anti-PD-1 antibody, nivolumab, in patients with platinum-resistant ovarian cancer. J. Clin. Oncol.33(34), 4015–4022 (2015).
- Muro K , BangY, ShankaranV, GevaRet al. A Phase 1b study of pembrolizumab (Pembro; MK-3475) in patients (Pts) with advanced gastric cancer. Ann. Oncol.25(5), 1–41 (2014).
- Plimack ER , GuptaS, BellmuntJet al. A Phase 1b study of pembrolizumab (Pembro; MK-3475) in patients (Pts) with advanced urothelial tract cancer. Ann. Oncol.25(Suppl. 5), v1–v41 (2014).
- Scott AJ , BendellJC, TaylorMHet al. Phase I/II study of nivolumab with or without ipilimumab for treatment of recurrent small cell lung cancer (SCLC): CA209-032. J. Clin. Oncol.33(Suppl.), Abstract 7503 (2015).
- Le DT , UramJN, WangHet al. PD-1 blockade in tumors with mismatch-repair deficiency. N. Engl. J. Med.26, 2509–2520 (2015).
- Nghiem P , BhatiaS, DaudAet al. Activity of PD-1 blockade with pembrolizumab as first systemic therapy in patients with advanced Merkel cell carcinoma. Presented at: The European Cancer Congress (ECC 2015). Vienna, Austria, 25–29 September 2015 ( Abstract 22LBA).